Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Insulin Glargine

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05286242Completed

Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients

NCT07461103Phase 2Completed

Effect of Topical Insulin on Healing Rate of Pemphigus Lesions

Showing all 2 trials

Research Network

Common Treatments

  • Insulin Glargine1
  • Covid19 Vaccine1
  • Human Insulin1
  • 09 Normal Saline1

Active Sponsors

  • Robert Leet and Clara Guthrie Patterson Trust1
  • Alexandria University1
  • National Institute of Allergy and Infectious Diseases (NIAID)1
  • Yale University1

Top Investigators

Related Conditions

  • Multiple Sclerosis1
  • Bcell Deficiency1
  • Pemphigus Vulgaris1
  • Skin Erosion1

Activity Timeline